Warning: DOMDocument::load(http://www.iovs.org/rss/current.xml) [domdocument.load]: failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php on line 322

Warning: DOMDocument::load() [domdocument.load]: I/O warning : failed to load external entity "http://www.iovs.org/rss/current.xml" in /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php on line 322

Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/site/Site.inc.php on line 271

Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/site/Site.inc.php on line 273
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty - eyeNEWS — Все новости офтальмологии. Версия 6.0
askin_heid
glaucoma_net_ru
ВК
oftalmolog_club
nidek
YouTube
Шахматы
Торика
bannerparasol
camopht
Первая пятница декабря
Конгресс 2014
appstore
профессор
icgs2018
Конгресс
medlab
www.worldglaucoma.org
Основные мероприятия ассоциации офтальмологов
Mobile
Флаги
icglaucoma.org
Beaver
varthamana2
Ассоциации
santen
eye5
facebook
АйНьюс.РФ
конгресс 2018
Главная / Новости / A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
3 месяца назад
13 февраля 2018

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

Полный текст тут https://www.dovepress.com/articles.php?article_id=36765 

Mahmoud A Khaimi

Dean McGee Eye Institute, Oklahoma City, OK, USA

Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty.
Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications.
Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (P<0.001) at all time points postoperatively. Complete (no IOP-lowering medication) or qualified (use of ≤2 IOP-lowering medications) surgical success was achieved in 78.8% and 90.6% of eyes, respectively, at month 6 and 63.4% and 92.7% of eyes at month 36. The most frequently observed postoperative complication was hyphema in 48.7% (126/259) eyes at day 1, which decreased to 0.4% (1/244) of eyes by month 1. IOP ≥30 mmHg was noted in 13 (5.3%) eyes at postoperative week 1 and rarely thereafter, and no patient discontinued therapy because of an IOP increase.
Conclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.


Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/cms/includes/utils/Cookie.inc.php on line 60
Голосование
Что "заставляет" Вас заниматься научными исследованиями?